National Alzheimer’s Drug Registry Will Track Real-World Results

A new national registry, sponsored by the Alzheimer’s Association, will track real-world outcomes data for Alzheimer’s patients receiving FDA-approved treatments for the disease, including the antiamyloid antibody Aduhelm.

Maria Carillo, the group’s chief science officer, announced the new National Treatment and Diagnostic Alzheimer’s Registry during the opening session of the Clinical Trials in Alzheimer’s Disease meeting, one of the world’s most important gatherings of Alzheimer’s trialists and academics.

The registry will provide the data needed to bridge the gap between study results and real-world outcomes for patients, she said at the meeting. It could have profound impact not only on prescribing patterns, but on coverage decisions by public and private payers.

“This will allow stakeholders to track long-term performance of these therapies using real-world evidence. In addition to supporting scientific efforts, this registry will equip government funding and regulatory agencies with vital information to guide policy, education, approval and grantmaking decisions,” Carrillo said.